GLP-1 'Maintenance Dosing' Could Be the Key to Keeping Weight Off
Two landmark trials published this week suggest a lower, sustained GLP-1 dose may be the missing piece in long-term weight management.
All the sources I need are in. Let me now write the article.
Most people who stop a GLP-1 drug gain most of the weight back within a year. That single fact has quietly been the biggest unsolved problem in obesity medicine — until this week, when two major trials dropped at once and pointed toward the same answer: you may not need to keep climbing to the highest dose forever.
What Just Broke This Week
On May 12–14, 2026, a cluster of data landed that's reshaping how doctors and patients think about long-term GLP-1 use. Everyday Health reported that "maintenance dosing" — using a lower, stabilizing dose of a GLP-1 after you've hit your weight goal — could be the key to keeping weight off long-term. And the trial data backing that idea is now peer-reviewed and published.
Two studies drove the conversation: one on tirzepatide (Zepbound), one on orforglipron — an oral GLP-1 that doesn't require injections.
BioPharma Dive noted that Lilly's data point specifically to "maintenance strategies" — a phrase that until recently wasn't part of the standard prescribing playbook.
The SURMOUNT-MAINTAIN Trial (Tirzepatide)
The first study is the one you'll be hearing about for months. Published in The Lancet on May 12, 2026, the SURMOUNT-MAINTAIN trial looked at whether people with obesity who'd already lost significant weight on tirzepatide could maintain that loss on a lower dose — rather than staying on the maximum dose or stopping entirely.
The trial was multicentre, double-blind, randomized, and placebo-controlled — the gold standard design. The researchers, led by Dr. Dana Horn and Dr. Louis Aronne, tested whether a step-down maintenance strategy could hold the weight off compared to placebo.
According to PR Newswire's report on Lilly's data, lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy.
The ATTAIN-MAINTAIN Trial (Orforglipron)
The second study is arguably the more novel one. Published in Nature Medicine on May 13, 2026, the ATTAIN-MAINTAIN trial tested orforglipron — a daily oral pill — for weight maintenance after initial GLP-1-driven weight loss.
The phase 3b trial is now complete, according to ClinicalTrials.gov (NCT06584916). Its main goal: evaluate whether orforglipron can maintain body weight reduction in people with obesity or overweight with weight-related conditions.
Why does the oral angle matter? Because one of the biggest real-world barriers to long-term GLP-1 use is the injection. A pill-based maintenance option — potentially at a lower dose and lower cost than the active weight-loss phase — could change who stays on treatment and for how long.
Why People Regain Weight When They Stop
This isn't about willpower. According to MedlinePlus (NIH), obesity is classified as a disease — one that involves complex hormonal and metabolic factors, not just calorie math. GLP-1 drugs work by mimicking hormones that regulate appetite and blood sugar. When you stop, those signals go quiet again.
A 2025 systematic review and meta-analysis published in Obesity Reviews looked specifically at what happens to body composition after discontinuing GLP-1 receptor agonists. The findings confirm what many people experience firsthand: stopping the drug is associated with significant weight regain.
The FDA's label for Wegovy (semaglutide) actually addresses this directly. According to the FDA-approved Wegovy label, the drug is indicated to "reduce excess body weight and maintain weight reduction long term" — meaning long-term use was always part of the design. The problem is that "long-term" at maximum dose comes with cost, side effects, and access barriers that push people to stop.
Maintenance dosing tries to thread that needle: stay on the drug, but at a dose your body and budget can actually sustain.
What We Still Don't Know
This is promising, but it's not a complete answer yet. A few open questions:
How low can you go? The trials tested specific lower doses — not a free-for-all step-down. What the right maintenance dose is for you depends on factors your prescriber has to assess.
Does it work forever? These trials have defined follow-up windows. Whether a maintenance dose holds weight off at year 3, 5, or 10 is still being studied.
Cost and coverage. Lower doses may mean lower drug costs, but insurance coverage for "maintenance" GLP-1 use remains inconsistent. That's a policy fight still in progress.
What This Means for You
- Stopping isn't the only option when you hit your goal. The new data suggest a lower maintenance dose may protect your results — ask your prescriber if that's a conversation worth having.
- Weight regain after stopping GLP-1s is a documented biological pattern, not a personal failure. According to the Obesity Reviews meta-analysis, it's a known effect of discontinuation.
- An oral maintenance option (orforglipron) may be on the horizon. It's not FDA-approved for this use yet, but the ATTAIN-MAINTAIN phase 3b data published this week is a significant step toward that becoming a real option.
Not medical advice. Talk to your prescriber about your situation — including what the right dose strategy looks like for you specifically.
